We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





End-to-End Diagnostic Platform Could Be Game Changer for En-Masse, Rapid and Precise COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article
Image: Dotz Mega-Diagnostic Platform (Photo courtesy of Dotz Nano Ltd.)
Image: Dotz Mega-Diagnostic Platform (Photo courtesy of Dotz Nano Ltd.)

A new diagnostic platform could be a game-changing, end-to-end solution for en-masse, rapid and precise diagnosis of COVID-19 and other viruses at the point-of-care (POC).

Dotz Nano Ltd.’s (Kefar-Sava, Israel) Mega-Diagnostic Platform is an all-in-one solution that consists of proprietary DOTZ Test Kits, an integrated diagnostic system, and a results-management system. The Dotz Mega-Diagnostic Platform is based on RT-LAMP (Loop-Mediated Isothermal Amplification) technology with >95% true positive rate for viral loads of 1250 copies per mL; and 100% specificity.

Dotz’s platform provides an integrated and cost-efficient solution for SARS-CoV-2 testing that has the capacity to simultaneously test up to 96 samples per device in approximately 30 minutes. The test produces a visually-detectable change in the color of samples, ensuring a simple and rapid analysis procedure. The platform can use both saliva and nasopharyngeal samples for a more comfortable testing experience, particularly for children.

The Dotz Mega-Diagnostic Platform can be used in organizations or locations that are required to perform large numbers of tests in a short time, such as airports, universities, factories, workplaces, border crossings, and more. It requires minimal operator training, thereby significantly lowering overhead costs such as medical personnel and laboratory equipment. Dotz’s diagnostic solution has been granted CE Mark Authorization from the European Union, and it has also applied for Emergency Use Authorization from the FDA. Dotz will showcase its Mega-Diagnostic Platform for the first time at the MEDICA 2021 Trade Fair in Dusseldorf, Germany, November 15-18th.

“From the outbreak of the pandemic up to this point, en-masse and accurate detection of COVID-19 relied on complex and slow methods that must be performed in well-equipped laboratories by trained personnel,” said Gideon Shmuel, CEO of Dotz. “Our integrated, simple-to-use solution brings rapid and highly-accurate testing capabilities to the field, supporting a resumption of normal economic activity while keeping those transiting highly-trafficked public spaces healthy and safe.”

Related Links:
Dotz Nano Ltd. 

Gold Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
New
Automatic Photometer
JOLLY 103
New
Automated Pathology Workstation
NanoMtrx 100 & 300
New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.